BioSpace News Archive

SCYNEXIS, Inc. (NASDAQ : SCYX) today announced the closing of its previously announced underwritten public offering of 38,888,889 shares of common stock and warrants to purchase up to 38,888,889 shares of common stock

Gateway Health and Dasher are pleased to announce a major milestone with the birth of their 600th baby.

A coalition of technology partners announced today that they have demonstrated the mass digitalization of pharmaceutical tablets and their linkage to a Trillian based trust ledger.

JDRF, the leading global organization funding type 1 diabetes (T1D) research, announced that it has committed 23 training grants, totaling more than $8 million in new funds to accelerate T1D research and the next generation of T1D experts, representing 9 states, as well as Australia, France, Canada, Germany, Denmark, Switzerland and the United Kingdom, in partnership with 20 institutions.

John Shegerian, Co-Founder and Executive Chairman of ERI delivered an informative keynote presentation at the Capital Roundtable event, “Treasure in the Trash: Where PE Firms are Finding Success in Waste and Recycling” at the University Club in Manhattan.

Axonics Modulation Technologies, Inc. announced that the underwriters of its follow-on public offering exercised in full their option to purchase an additional 750,000 shares of common stock from Axonics at the offering price of $22.00 per share, less underwriting discounts and commissions.

Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that it has entered into a feasibility evaluation with Genentech, a member of the Roche Group.

Lannett Company, Inc. (NYSE: LCI) today announced that it expects to commence marketing in the coming months a generic version of Adderall XR®, an extended-release mixed salt of a single entity Amphetamine tablet product (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate), with strengths of 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg tablets

Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, and Biocon Ltd (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, today announced that they have expanded their collaboration and license agreement for itolizumab to grant Equillium exclusive rights for developing and commercializing itolizumab in Australia and New Zealand.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has signed a joint marketing agreement in the United States with Fortelinea Software Systems that allows for the linking of Roche’s VENTANA Connect middleware with Fortelinea’s Prima lab tracking and management system to improve workflow for automated immunohistochemistry (IHC) and in-situ hybridization (ISH) testing in U.S. research laboratories.